Literature DB >> 15771023

[Assessment of chloroquine resistance two years after stopping chemoprophylaxis in 0 to 9-year-old children living in a malaria-endemic village of Mali].

H Sangho1, A Diawara, M Diallo, S Sow, H A Sango, M Sacko, O Doumbo.   

Abstract

This study was carried out in the village of Faladié, Mali located in the malaria-endemic Kati region, two years after routine use of chloroquine prophylaxis was discontinued in children 0 to 9 years old. The main purpose of this study was to assess changes in chloroquine resistance. Two cross-sectional surveys in association with WHO in vivo chloroquine sensitivity testing were conducted, i.e., one in September 2000 and one in December 2002. Findings in 2000 showed that 77.5% of mothers administered chloroquine prophylaxis to their children in compliance with physician orders. The plasmodic index was 62%. The overall level of parasitologic resistance (based on the 1996 WHO in vivo tests) was 80%. The overall therapeutic failure rate was 17.5%. Findings in 2002 demonstrated a plasmodic index of 28%, an overall parasitologic resistance rate of 45% (based on WHO in vivo tests), and an overall therapeutic failure rate of 15%. The diminution of resistance in 2002 may be due to the decrease of drugs pressure and to low exposure of individuals to mosquitoes at the end of transmission season. Althougt these data indicate a 44% drop in chloroquine resistance (P=0.0001), no increase in the clinical efficacy of chloroquine was observed (P=0.05). In view of these results we propose more emphasis on information campaigns to increase public awareness of the need for chemoprophylaxis only for pregnant women, on the promotion of the use of bednets and insecticide-impregnated materials, and on environmental management.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15771023

Source DB:  PubMed          Journal:  Med Trop (Mars)        ISSN: 0025-682X


  3 in total

1.  A molecular map of chloroquine resistance in Mali.

Authors:  Abdoulaye A Djimde; Breanna Barger; Aminatou Kone; Abdoul H Beavogui; Mamadou Tekete; Bakary Fofana; Antoine Dara; Hamma Maiga; Demba Dembele; Sekou Toure; Souleymane Dama; Dinkorma Ouologuem; Cheick Papa Oumar Sangare; Amagana Dolo; Nofomo Sogoba; Karamoko Nimaga; Yacouba Kone; Ogobara K Doumbo
Journal:  FEMS Immunol Med Microbiol       Date:  2009-11-02

2.  Efficacy of sulphadoxine-pyrimethamine + artesunate, sulphadoxine-pyrimethamine + amodiaquine, and sulphadoxine-pyrimethamine alone in uncomplicated falciparum malaria in Mali.

Authors:  Hamma Maiga; Abdoulaye A Djimde; Abdoul H Beavogui; Ousmane Toure; Mamadou Tekete; Cheick Papa O Sangare; Antoine Dara; Zoumana I Traore; Oumar B Traore; Souleymane Dama; Christelle N'Dong; Hamidou Niangaly; Nouhoum Diallo; Demba Dembele; Issaka Sagara; Ogobara K Doumbo
Journal:  Malar J       Date:  2015-02-07       Impact factor: 2.979

3.  Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali.

Authors:  Kassoum Kayentao; Hamma Maiga; Robert D Newman; Meredith L McMorrow; Annett Hoppe; Oumar Yattara; Hamidou Traore; Younoussou Kone; Etienne A Guirou; Renion Saye; Boubacar Traore; Abdoulaye Djimde; Ogobara K Doumbo
Journal:  Malar J       Date:  2009-01-07       Impact factor: 2.979

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.